Black Diamond Therapeutics (BDTX)
(Delayed Data from NSDQ)
$4.76 USD
-0.02 (-0.42%)
Updated Sep 20, 2024 04:00 PM ET
After-Market: $4.80 +0.04 (0.84%) 7:58 PM ET
3-Hold of 5 3
D Value A Growth A Momentum B VGM
Brokerage Reports
0 items in cart
Black Diamond Therapeutics, Inc. [BDTX]
Reports for Purchase
Showing records 1 - 20 ( 93 total )
Company: Black Diamond Therapeutics, Inc.
Industry: Medical - Drugs
Biotechnology- ESMO 2024 Abstract Titles for Covered Companies
Provider: Wedbush Securities Inc.
Analyst: NIERENGARTEN D
Company: Black Diamond Therapeutics, Inc.
Industry: Medical - Drugs
Company: Black Diamond Therapeutics, Inc.
Industry: Medical - Drugs
Q2 Financials; Rich Story Nears its Next Chapter
Provider: Wedbush Securities Inc.
Analyst: DRISCOLL R
Company: Black Diamond Therapeutics, Inc.
Industry: Medical - Drugs
BDTX-1535 Continues to Show Promise in Brain Cancer; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: BURNS R
Company: Black Diamond Therapeutics, Inc.
Industry: Medical - Drugs
Company: Black Diamond Therapeutics, Inc.
Industry: Medical - Drugs
BDTX-1535 On the Brain; IST Confirms Brain Penetrance, Activity
Provider: Wedbush Securities Inc.
Analyst: DRISCOLL R
Company: Black Diamond Therapeutics, Inc.
Industry: Medical - Drugs
Biotechnology -ASCO 2024 Abstract Roundup for Covered Companies
Provider: Wedbush Securities Inc.
Analyst: Research Department
Company: Black Diamond Therapeutics, Inc.
Industry: Medical - Drugs
Several Datasets Expected This Year; 1Q24 Financials; Modulating PT to $11
Provider: H.C. Wainwright & Co., Inc.
Analyst: BURNS R
Company: Black Diamond Therapeutics, Inc.
Industry: Medical - Drugs
Q1 Financials; Well-Positioned for Key Stretch of Data Readouts
Provider: Wedbush Securities Inc.
Analyst: DRISCOLL R
Company: Black Diamond Therapeutics, Inc.
Industry: Medical - Drugs
Biotechnology- ASCO 2024 Abstract Titles for Covered Companies
Provider: Wedbush Securities Inc.
Analyst: Research Department
Company: Black Diamond Therapeutics, Inc.
Industry: Medical - Drugs
ASCO 2024 Abstract Titles for Covered Companies
Provider: Wedbush Securities Inc.
Analyst: NIERENGARTEN D
Company: Black Diamond Therapeutics, Inc.
Industry: Medical - Drugs
Company: Black Diamond Therapeutics, Inc.
Industry: Medical - Drugs
Landscape Analysis Reinforces BDTX-1535 Opportunity; Raising PT to $16
Provider: Wedbush Securities Inc.
Analyst: DRISCOLL R
Company: Black Diamond Therapeutics, Inc.
Industry: Medical - Drugs
Company: Black Diamond Therapeutics, Inc.
Industry: Medical - Drugs
Data Updates Expected Later this Year; 2023 Financials Reported; Modulating PT to $12
Provider: H.C. Wainwright & Co., Inc.
Analyst: BURNS R
Company: Black Diamond Therapeutics, Inc.
Industry: Medical - Drugs
Company: Black Diamond Therapeutics, Inc.
Industry: Medical - Drugs
Q4 Financials; GBM Ph1 Update in 2Q:24; BDTX-1535 Ph2 NSCLC Data in 3Q:24
Provider: Wedbush Securities Inc.
Analyst: DRISCOLL R
Company: Black Diamond Therapeutics, Inc.
Industry: Medical - Drugs
AACR 2024 Abstract Roundup for Covered Companies
Provider: Wedbush Securities Inc.
Analyst: NIERENGARTEN D
Company: Black Diamond Therapeutics, Inc.
Industry: Medical - Drugs
Expected 2024 Milestones Announced; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: BURNS R
Company: Black Diamond Therapeutics, Inc.
Industry: Medical - Drugs
Green Light for First-Line NSCLC Study; Key Updates Set Up Busy 2024
Provider: Wedbush Securities Inc.
Analyst: DRISCOLL R